Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FGFR2 amplification

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

FGFR2 amplification	Gastric Cancer	FGFR2 amplification	Gastric Cancer	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2
FGFR2 amplification	Cholangiocarcinoma	FGFR2 amplification	Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2
FGFR2 amplification	Gastroesophageal Cancer	FGFR2 amplification	Gastroesophageal Cancer	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR2 amplification	Gastric Cancer	FGFR2 amplification	Gastric Cancer	AMG 552 Sensitive: C2 – Inclusion Criteria AMG 552 Sensitive : C2	AMG 552 Sensitive: C2 – Inclusion Criteria AMG 552 Sensitive : C2
FGFR2 amplification	Gastroesophageal Junction Adenocarcinoma	FGFR2 amplification	Gastroesophageal Junction Adenocarcinoma	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR2 amplification	Gastric Cancer	FGFR2 amplification	Gastric Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR2 amplification	Triple Negative Breast Cancer	FGFR2 amplification	Triple Negative Breast Cancer	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2
FGFR2 amplification	Gastric Cancer	FGFR2 amplification	Gastric Cancer	Debio 1347 Resistant: C3 – Early Trials Debio 1347 Resistant : C3	Debio 1347 Resistant: C3 – Early Trials Debio 1347 Resistant : C3
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3